PTEN has been used as the basis for the transgenic modelling of prostate cancers, and this has revealed that deletion of this tumour suppressor leads to the activation of SREBP1, a transcription factor that regulates lipogenic genes (34). This evidence concerns the gene PTEN and prostate cancer.